Meanwhile, according to TCGA data [Prostate Adenocarcinoma (TCGA, PanCancer Atlas)], PKD1/2/3 expression in prostate cancer, at mRNA levels, are upregulated in about 4–5% tumors (Additional file 3: Figure S1), suggesting that it is not so much about overexpression or amplification in tumors, the aberrant activation of PKD1/2/3 may plays a more important role in tumor progression. This evidence concerns the gene PKD1 and neoplasm.